Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) has received firm commitments to undertake a $22 million placement
  • All up, 34 million new fully-paid ordinary shares will be issued to investors at 65 cents
  • This price represents a 30.5 per cent discount on LGP’s trading price of 93.5 cents on February 4
  • LGP is also planning to undertake a share purchase plan to raise up to $5 million
  • Eligible shareholders will be able to subscribe for up to $30,000 worth of shares without incurring any brokerage or transmission costs
  • LGP will use the money to speed-up sales and marking efforts in both Australia and overseas, and expand its manufacturing and cultivation capacity
  • LGP is down 14.4 per cent and shares are trading at 80 cents

Little Green Pharma (LGP) has received firm commitments to undertake a $22 million placement.

The medical cannabis company entered a trading halt on February 5 but did not disclose how much it would be raising or what the funds would be used for.

All up, 34 million new fully-paid ordinary shares will be issued to investors at 65 cents.

This price represents a 30.5 per cent discount to LGP’s trading price of 93.5 cents on February 4, and an 8.4 per cent discount to the 20-day volume-weighted average price.

Shares are expected to settle on or around February 15.

LGP is also planning to undertake a share purchase plan to raise up to $5 million.

Eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which will be priced the same as the placement of 65 cents.

The plan will open on February 15 and close on March 3. Shares will be allocated on March 11 and begin trading on the ASX on March 12.

LGP will use the money from both the placement and share purchase plan to speed-up sales and marking efforts in both Australian and overseas markets, and expand its manufacturing and cultivation capacity.

“Little Green Pharma has gone from strength to strength, and has achieved immense growth in the last year, most recently setting new records to quarterly revenue, unit sales, and patient numbers,” Managing Director Fleta Solomon said.

“We expect the next 12 months to be very exciting for the company and look forward to reporting on our continued success,” she added.

LGP is down 14.4 per cent and shares are trading at 80 cents at 1:58 pm AEDT.

LGP by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.